Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Publication year range
1.
Acta Otolaryngol ; 135(12): 1205-11, 2015.
Article in English | MEDLINE | ID: mdl-26245698

ABSTRACT

CONCLUSION: Clinical studies and meta-analyses demonstrated that betahistine is effective and safe in the treatment of Ménière's disease, BPPV (benign paroxysmal positional vertigo), vestibular neuronitis, and other types of peripheral vertigo. OBJECTIVES: The goal of this paper is to review the pharmacological profile of betahistine and the evidence for its effectiveness and safety in the treatment of peripheral vertigo. METHODS: Selection criteria for the publications on betahistine included randomized clinical trials that evaluated the effectiveness and safety of betahistine vs placebo or active control in the treatment of peripheral vertigo. Recent meta-analyses were also included. Databases searched included PubMed, the Cochrane Ear, Nose and Throat Disorders Group Trials Register, and ICTRP. The review also presents an update on the mechanisms of action, pharmacodynamics, and pharmacokinetics of betahistine. RESULTS: Efficacy and safety of betahistine has been demonstrated in numerous clinical trials. The precise mechanism of action of betahistine is still not completely understood, but the clinical experience demonstrated the benefit of betahistine in different types of peripheral vertigo. In more than 40 years of clinical use, betahistine has shown an excellent safety profile with the usual dose range from 8-48 mg daily. According to clinical studies, betahistine 48 mg daily during 3 months is an effective and safe option for the treatment of peripheral vertigo.


Subject(s)
Betahistine/therapeutic use , Postural Balance/drug effects , Quality of Life , Vertigo/drug therapy , Vestibule, Labyrinth/drug effects , Histamine Agonists/therapeutic use , Humans , Vertigo/physiopathology , Vestibule, Labyrinth/physiopathology
2.
Acta otorrinolaringol ; 11(2): 69-73, nov. 1999. tab
Article in Spanish | LILACS | ID: lil-308981

ABSTRACT

Se realizó un estudio retrospectivo de casos de Angiofibroma Nasofaríngeo juvenil desde Enero a Agosto de 1998, con el objetivo de determinar las características de presentación, las vías de abordaje y su relación con tumor residual. Ingresaron al estudio 7 casos, todos con TAC preoperatoria y postoperatoria, que nos permitió estudiar los tumores y evaluar la enfermedad residual. Todos los pacientes resultaron varones, el promedio de edad fue 16 años. Epistaxis 7 (100 por ciento) y obstrucción nasal 4 (57 por ciento), fueron los síntomas más frecuentes. Un caso era estadio I, 6 (86 por ciento) estaban en estadio II. En 3 (43 por ciento) pacientes se presentó tumor residual, 2 (29 por ciento) en estadio II y uno en estadio I. Las técnicas utilizadas fueron el degloving, la rinotomía lateral y el abordaje transnasal con similares tasas de recurrencia de la enfermedad. El angiofibroma Nasofaríngeo Juvenil se presenta exclusivamente en varones, jóvenes, el diagnóstico temprano permite instaurar tratamiento precoz por lo que son poco frecuentes los estadios más avanzados, no parece haber relación entre la técnica de abordaje y la recurrencia del tumor. El abordaje transnasal para tumores hasta estadio II es una alternativa óptima por los resultados estéticos faciales y tasa de recurrencia similar a las vías convencionales


Subject(s)
Humans , Male , Adult , Angiofibroma , Nasal Cavity , Pharynx , Medicine , Otolaryngology , Venezuela
SELECTION OF CITATIONS
SEARCH DETAIL
...